Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Impairment expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Zomedica

Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. It offers products for dogs and cats by focusing on the unmet needs of clinical veterinarians. Its TRUFORMA biosensor platform is designed to assist practitioners in the diagnosis of complex conditions. The company was founded by Gerald L. Solensky. on January 7, 2013 and is headquartered in Ann Arbor, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zomedica reports revenue growth and product advancements amidst profitability challenges

Zomedica's 2022 performance reflects revenue growth and product advancements, though challenges in profitability persist. The company's strategic focus on companion animal healthcare presents growth opportunities through innovation and market stability. Addressing expense management, stock stability, and leveraging market trends will be key for Zomedica's future success.

Zomedica reports robust Q1 earnings, eyes global equine market

Zomedica's Q1 2023 showcased strong revenue growth, particularly driven by TRUFORMA and international sales.
The company's focus on maintaining margins, expanding marketing efforts, and targeting global equine markets positions it for future success.
Challenges include the closure of the cancer assay program and operational hurdles in achieving the 70% gross margin target.
Opportunities lie in the launch of new assays, international expansion, and investor engagement beyond quarterly updates.

Zomedica reports robust Q2 earnings, eyes international expansion and product launches

Zomedica's Q2 performance reflects strong revenue growth and strategic investments for future profitability.
Despite challenges like increased OpEx and lower margins, the company is focused on long-term growth through product launches and market expansion.
Opportunities lie in international market exploration, upcoming product launches, and investor engagement strategies.

Zomedica reports record revenues, eyes global expansion amidst stock challenges

Zomedica's Q3 performance reflects strong revenue growth and strategic acquisitions, despite facing challenges like potential delisting and net losses.
The company's focus on new product launches, international expansion, and partnerships presents opportunities for future growth and market diversification.
Overall, Zomedica aims to drive towards cash flow breakeven by leveraging innovative products and maintaining a strong liquidity position.

Zomedica reports record revenues, eyes profitability through strategic growth

Zomedica's strong financial performance in Q4 2023 and full-year results, coupled with a robust cash position and strategic growth initiatives, position the company for future success.
While facing challenges related to compliance requirements and integration costs, Zomedica's focus on innovation, market expansion, and profitability goals present opportunities for sustained growth.
By balancing operational efficiency, product development, and financial discipline, Zomedica aims to drive revenue growth, enhance market presence, and deliver long-term value to shareholders.

Zomedica reports revenue growth and strong cash position in Q1

Zomedica's Q1 2024 performance showed revenue growth driven by key segments, strong cash position, and focus on operational efficiency. The company faces challenges in managing expenses and achieving aggressive revenue targets. Opportunities lie in expanding product lines, international sales, and maintaining financial strength.

Zomedica reports Q2 revenue growth amidst challenges and opportunities

Zomedica's Q2 performance showed revenue growth but with challenges in sales force and noncash charges.
Strengths include achieving milestones and expanding facilities, while opportunities lie in international expansion.
The company faces the task of managing cash burn and finding a new CFO.
Expectations for the second half of 2024 include revenue growth and operational focus.

Zomedica reports record Q3 revenue, eyes global expansion opportunities

Zomedica's Q3 2024 performance showcased revenue growth, margin strength, and cost reduction efforts, positioning the company for future profitability. Strategic international partnerships and product innovations underscore growth potential.
While challenges in achieving profitability persist, Zomedica's focus on operational efficiency and global expansion presents opportunities for sustained growth. Addressing investor inquiries and executing on strategic initiatives will be key to unlocking future value.
With a solid cash position, ongoing product enhancements, and expansion into new markets, Zomedica is poised for growth. Clear communication on financial targets, operational milestones, and strategic direction will be crucial for investor confidence and market success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Gritstone Oncology Inc

Ocugen, Inc.

Could These 3 Stocks Be 10-Baggers in 2021?

Allied Esports Entertainment Inc

Genius Brands

Ideanomics Inc

Cenntro Electric Group

SNDL Inc.

trivago

The jury may still be out on their future price movements, but these seven Reddit stocks, trading at penny stock levels, remain popular plays among the WSB community. The post 7 Penny Stocks Flying High on Reddit Stocks Chatter appeared first on InvestorPlace.

7 Penny Stocks Flying High on Reddit Stocks Chatter

Chico's FAS

Castor Maritime Inc

Nokia

OrganiGram Holdings Inc.

Rave Restaurant Group

Tuniu Corp

Analysts and economists are expecting the U.S. economy to significantly accelerate in coming quarters as the coronavirus vaccine rollout facilitates the reopening of many businesses and the unlocking of pent-up demand in hard-hit segments of the economy, including restaurants, travel and retail. With the next round of $1,400 stimulus payments set to go out starting this weekend, some of the most popular stocks among younger retail traders could get a major boost ahead of the economic reopening.

8 Reopening Stocks Under $5

Thanks to its cost-saving pet diagnostics platform, many investors are turning positive on Zomedica. Is now the time to strike with ZOM stock?

Is the Price Finally Right for Much-Loved Zomedica Stock?

It could be a good growth pick, but it probably won't repeat its recent blastoff.

Should You Buy Zomedica Stock in March?

The market suddenly is paying more attention to valuation. That's a problem for ZOM stock, which looks drastically overvalued from any angle.

The Math Doesn't Work: Zomedica Stock Has Further to Fall

Nevertheless, with little reason for it to rally further, but with it still vulnerable to another move lower, skip out on ZOM stock, and look elsewhere for high-risk, but high-potential, opportunities. The post Zomedica Stock Could Hold Steady, but It's Hardly a Buy at Today's Prices appeared first on InvestorPlace.

Zomedica Stock Could Hold Steady, but It's Hardly a Buy at Today's Prices

There's plenty and growing reasons off and on the price chart for ZOM stock investors to be appreciatively upbeat about. The post Why $5 in Zomedica Stock Looks Possible appeared first on InvestorPlace.

Why $5 in Zomedica Stock Looks Possible

Zomedica's first product, Truforma, goes on sale at the end of the month. Will the nation's love of pets spur ZOM stock to profitability?

Things Are About to Get Interesting for Zomedica

TRUFORMA® Progressing Toward Commercialization TRUFORMA® Progressing Toward Commercialization

Zomedica Retires Preferred Shares

AMC Entertainment

Express

GameStop

Jaguar Health

Koss

These seven meme stocks have been caught up in the short squeeze, and have grown immensely despite showing little promise from their fundamentals. The post 7 Meme Stocks That Have Retail Traders ‘Stonk-ing' Up appeared first on InvestorPlace.

7 Meme Stocks That Have Retail Traders ‘Stonk-ing' Up

This pet health company has made a few investors rich already, but more is still to come.

Why Is Everyone Talking About Zomedica Stock?

Both are highfliers with intriguing potential.

Better Reddit Stock: Ocugen vs. Zomedica

The prevailing logic as I see it is that the rising tide of the pet industry is going to float all boats, including ZOM stock. But the facts simply don't bear this out over the long term.

Zomedica Lacks Hard Numbers To Back Up Its Big Pets-n'-Pandemic Rally

As Zomedica prepares to launch Truforma, its first commercial product, ZOM stock continues to experience volatility. The post Zomedica Stock Volatility Continues as Truforma Launch Nears appeared first on InvestorPlace.

Zomedica Stock Volatility Continues as Truforma Launch Nears

There are heavy expectations for ZOM stock, even though Zomedica still has no revenues and a measured plan to roll out its Truforma device. The post It May Be Too Early to Believe in Zomedica Stock appeared first on InvestorPlace.

It May Be Too Early to Believe in Zomedica Stock

Zomedica is a winner with its pet lab product and cash balance. ZOM stock is worth as much as $3.61 following its Truforma product launch.

Zomedica Is a Winner With Its Pet Lab Product and Cash Balance

ZOM stock has been on a tear this year, and is nearing the buy zone with the impending release of its Truforma Platform The post Zomedica Continues to Fly High With Its Recent Positive Developments appeared first on InvestorPlace. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG It doesn't matter if you have $500 in savings or $5 million.

Zomedica Continues to Fly High With Its Recent Positive Developments

ZOM Stock has risen by more than 1,000% in the last three months as the launch of Truforma looms. However, Zomedica investors may in for a shocker.

ZOM Stock: Pros and Cons of Buying Zomedica Ahead of Key Product Launch

Zomedica (ZOM) stock is gaining on Monday following the release of its results for the full year of 2020 and approaching product launch. The post ZOM Stock: Why Zomedica Shares Are Zooming Higher Monday appeared first on InvestorPlace.

ZOM Stock: Why Zomedica Shares Are Zooming Higher Monday

On paper, the narrative for ZOM stock is exciting because of the relevant pet care business. However, you should analyze its true fundamentals very carefully.

Don't Get Suckered into the Zomedica Trade

The stock price of Zomedica Corp (NYSEAMERICAN: ZOM) is trading at over 9% pre-market. This is why it happened.

ZOM Stock Price Increases Over 9% Pre-Market: Why It Happened

ANN ARBOR, Mich., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today reported consolidated financial results for the year ended December 31, 2020. Amounts, unless specified otherwise, are expressed in U.S. dollars and presented under accounting principles generally accepted in the United States of America (“U.S. GAAP”).

Zomedica Corp. Announces Year End 2020 Financial Results

In the meantime, the company still needs to execute the commercialization of Truforma. If it experiences any hiccups along the way, shares could fall back to lower price levels.

All Bets are Off Whether Zomedica Stock Grows Into Its Valuation

BlackBerry

Bed Bath & Beyond

Tilray Brands

The rallies in January's meme stocks clearly went too far. After big pullbacks, however, some of the names may still have a long-term case.

News for Zomedica Stock (ZOM)